Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fadraciclib in Advanced Solid Tumors and Lymphoma
2024-516289-12-00Phase 2Completed
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of fadraciclib in endometrial cancer (EC), ovarian cancer, biliary cancer and 7 more, sponsored by Cyclacel Pharmaceuticals, Inc. Primary endpoints: Dose-limiting toxicities (DLTs) in Phase 1 and Objective response rate (ORR) in Phase 2. Started Aug 2024; status: completed.
02
Drugs
fadraciclib
03
Conditions
endometrial cancer (EC)ovarian cancerbiliary cancerhepatocellular carcinoma (HCC)malignant B-cell neoplasm
Beyond the preview
Go deeper on 2024-516289-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516289-12-00.